Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China.

Frontiers in public health - 1 Jan 2026

Xu Kai, Yan Yuting, Cao Zhaoliu, Liu Jinchun, Yao Hongting, Sun Yuyang, Zhang Jingyu, Wu Hong

Abstract excerpt

Background: In the OptiTROP-Lung04 trial, sacituzumab tirumotecan (sac-TMT) yielded a median progression-free survival of 8.3 months-a clinically significant outcome that has approval by the National Medical Products Administration. This study evaluates the cost-effectiveness of sac-TMT as a later-line therapy for patients with EGFR-mutant advanced NSCLC who have progressed on EGFR-TKIs, from the perspective of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quality-Adjusted Life Years

Source

Open in PubMed Open full text

Identifiers

PMID: 42577174
DOI: 10.3389/fpubh.2026.1843636
PMCID: PMC13453752

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China.PMID 42577174Read ↗

Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-mutated advanced NSCLC in China.Semantic proximity Read ↗

Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of Sacituzumab tirumotecan versus Platinum-based chemotherapy for EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC in ChinaSemantic proximity Read ↗

Cost-Effectiveness of Sacituzumab Tirumotecan vs Chemotherapy for EGFR- TKI–Resistant NSCLC: Evidence to Inform Drug Pricing in the U.S. and ChinaSemantic proximity Read ↗

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.Semantic proximity Read ↗

Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.Semantic proximity Read ↗

Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB-IV EGFR-mutated NSCLC in China.Semantic proximity Read ↗

Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing.Semantic proximity Read ↗

Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.Semantic proximity Read ↗

Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.Semantic proximity Read ↗

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Semantic proximity Read ↗

Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.